Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023116 | 0.91 | SIGMAR1 (0.55) | KDM1AMAOAMAOBSIGMAR1MEN1 | |
| SCHEMBL23023136 | 0.82 | HTR5A (0.50) | SIGMAR1MEN1KMT2A | |
| SCHEMBL4482142 | 0.80 | KDM1A (0.46) | KDM1AMAOAMAOBSIGMAR1MEN1 | |
| SCHEMBL22495345 | 0.79 | SIGMAR1 (0.63) | MAOASIGMAR1MEN1KMT2ACHRM2 | |
| SCHEMBL26644568 | 0.78 | CHRM2 (0.53) | SMN1; SMN2MEN1RAB9AKMT2ACHRM2 | |
| SCHEMBL5208820 | 0.76 | CHRM2 (0.55) | SMN1; SMN2MEN1KMT2ACHRM2ALDH1A1 | |
| SCHEMBL23022866 | 0.76 | SIGMAR1 (0.69) | MAOASIGMAR1MEN1KMT2ACHRM2 | |
| SCHEMBL10425868 | 0.76 | SIGMAR1 (0.73) | MAOASIGMAR1MEN1RAB9AKMT2A | |
| SCHEMBL13136967 | 0.76 | MTOR (0.47) | OPRM1OPRD1OPRK1 | |
| SCHEMBL375157 | 0.75 | MEN1 (0.75) | KDM1AMEN1RAB9AKMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | KDM1A 1250/4885MAOA 364/4885MAOB 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.